Community Health Media
Avsnitt

Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

Community Health Media
Dela

A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment.


The conversation explores:

  • Why DB09 may replace the CLEOPATRA standard
  • The significance of 40+ month median PFS
  • Complete response rates and treatment durability
  • Managing ILD, fatigue, nausea, and alopecia
  • Maintenance therapy strategies
  • PATINA and HER2CLIMB-05 insights
  • Sequencing after T-DXd progression
  • Why “saving your best drug for later” may no longer apply


This is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer.

–Thanks for watching!Our podcasts are also available on:


–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

  • Peer to peer interviews, panels & round-tables
  • Curated live events & conferences
  • Professional in-depth content & research updates
  • Interactive learning modules & webinars
  • Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Community Health Media. Innehållet i podden är skapat av Community Health Media och inte av, eller tillsammans med, Poddtoppen.